Thanks to all who attended the CU Anschutz Innovation Forum
CU Innovations, Startup Toolbox and Academia Industry Alliance (AIA) hosted a 3-day event on June 10-12th that highlighted the diversity of innovation at the University of Colorado Anschutz Medical Campus.
Engaging presentations and panel discussions demystified the innovation journey. Key sessions covered company formation, building inclusive teams and career opportunities. CU researchers, start-ups and industry partners participated and networked at this successful event!
Congratulations to the winners of the Venture Showcase: NowVitals, pitched by Robin Deterding, MD, and Vināśa Oncology, pitched by Sujatha Venkataraman, PhD!
(1/19)
(2/19)
(3/19)
(4/19)
(5/19)
(6/19)
(7/19)
(8/19)
(9/19)
(10/19)
(11/19)
(12/19)
(13/19)
(14/19)
(15/19)
(16/19)
(17/19)
(18/19)
(19/19)
Agenda
Building upon the success of last year's Stories of Women-Led Innovation Event, this forum continued highlighting the achievements and challenges faced by our women innovators and demystifying the innovation pathway through presentations and panel discussions. Sessions covered intellectual property protection, building inclusive teams and addressing bias in the context of academic innovation.
Attendees were excited to hear from our keynote speaker, Gitanjali Rao, aspiring scientist, inventor and author!
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
This event aimed to educate and inspire entrepreneurs at all stages. Featuring panels on company formation, funding biomedical discoveries and creating strategic alliances, each session included interactive elements and the chance to network with potential partners from the Anschutz campus and beyond.
Attendees got to know Jodie Morrison, CEO of Q32 Bio, and Kimberly Muller, Executive Director of CU Innovations, through their Fireside Chat Keynote.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Congratulations to the judge vote winner, NowVitals pitched by Robin Deterding, MD, and the audience vote winner, Vināśa Oncology pitched by Sujatha Venkataraman, PhD!
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
With sessions featuring scientific talks, career panels, and a 2-hour networking lunch, RMBTS offered a prime platform to highlight scientific advancements and career opportunities, and foster collaboration within Colorado's scientific community.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Jim Lambert, PhD
Founder & President, Vona Oncology
About Jim Lambert, PhD:
Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer. Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.
About Vona Oncology:
Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $2.65M in non-dilutive funds to date.
The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC. Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.
Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro, and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit.
Event Sponsors
Thank you to our sponsors for making this forum possible! We are greatly appreciative of your continued support.
PLATINUM SPONSORS:
SPONSORS:
